CVRx’s stock has risen nearly 20% after the company revealed that its heart failure device is set to be investigated in an ...

CVRx, Inc. initiates landmark BENEFIT-HF trial with FDA-approved Barostim device, aiming to expand heart failure patient ...

Study is Expected to Be One of the Largest Therapeutic Cardiac Device Trials in Heart Failure Ever Performed, and is ...

CVRx, Inc. a developer of neuromodulation solutions for patients with cardiovascular diseases, announced initiation of the ...

Chuck Moon, a congestive heart failure patient, experienced significant improvement in his quality of life after receiving a Barostim device implant. The Barostim device is a new technology that acts ...

CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and ...

CVRx, Inc. announced at the Technology and Heart Failure Therapeutics (THT) conference that new real-world evidence demonstrates significant reductions in hospital visits and length of stay after ...

A new device called Barostim is helping heart failure patients at Christ Hospital in Cincinnati live more normal lives without major surgery, as experienced by local grandfather Eric Townsend.For ...

CMS proposed to retain Barostim implant procedure in APC 1580 with a $45,000 outpatient payment, enhancing reimbursement for heart failure treatments. CVRx, Inc. announced that the Centers for ...

TUCSON, Ariz. (KVOA) - Carondelet St. Mary's Hospital has successfully completed its first implantation of the Barostim™ Baroreflex Activation Therapy device, marking a significant advancement in the ...

When medication stops working for people with congestive heart failure there are few options. A few months ago, Joe Knox couldn't take a simple walk due to his congestive heart failure. "I couldn't ...